Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Regeneron intends to update its full year 2022 financial guidance to reflect the Libtayo purchase during its second quarter 2022 earnings announcement in early August. With today's closing, Regeneron will now record 100% of global net sales and expenses for Libtayo. In 2015, Regeneron and Sanofi entered into the Immuno-oncology License and Collaboration Agreement whereby the companies split Libtayo's worldwide operating profits equally and co-commercialized Libtayo in the U.S., with Sanofi solely responsible for commercialization outside the U. The intent to purchase Libtayo was announced on June 2, 2022. (NASDAQ: REGN) today announced that it has completed the acquisition of Sanofi's stake in Libtayo ® (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. TARRYTOWN, N.Y., J/PRNewswire/ - Regeneron Pharmaceuticals, Inc. Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |